HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery? | RTCL.TV Social RTCL TV 0:57 11 months ago 12 Скачать Далее
HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review Conference Total Health | Oncology 25:20 1 year ago 2 144 Скачать Далее
Clinical outcomes in women with metastatic HER2-low breast cancer in the real world VJOncology 1:17 2 years ago 191 Скачать Далее
Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review Total Health | Oncology 2:06 1 year ago 92 Скачать Далее
Overview of the management of HER2-low breast cancer patients ecancer 7:13 1 year ago 127 Скачать Далее
Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate NEJM Group 11:25 4 months ago 50 Скачать Далее
The Science of HER2-low Breast Cancer and Implications for the Pathology Team ASCP 54:43 2 years ago 2 703 Скачать Далее
Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM NEJM Group 2:12 2 years ago 7 092 Скачать Далее
Treatment Options for HER2-Low Breast Cancer: All You Need to Know Yerbba – Breast Cancer 5:16 6 months ago 2 789 Скачать Далее
HER2-Low Breast Cancer: DESTINY or Good Science? Cancer Treatment Updates 11:12 6 months ago 15 642 Скачать Далее
HER2-low breast cancer: the ESMO Expert Consensus Statements European Society for Medical Oncology (ESMO) 2:02 1 year ago 943 Скачать Далее
New treatment for HER2 low metastatic breast cancer (HB 422) HealthBreak Dignity Health Central Coast 1:31 1 year ago 82 Скачать Далее
